scholarly journals Cyclin E Low-Molecular-Weight Isoform as a Predictor of Breast Cancer in Japanese Women

2011 ◽  
Vol 96 (3) ◽  
pp. 245-253 ◽  
Author(s):  
Yukiko Tokai ◽  
Shigeto Maeda ◽  
Junzo Yamaguchi ◽  
Tatsuya Uga ◽  
Naomi Hayashida ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Molecular Weight ◽  
Cancer Progression ◽  
Cyclin E ◽  
Tumor Grade ◽  
Proteolytic Processing ◽  
Receptor Expression ◽  
Low Molecular Weight ◽  
Breast Cancer Patients ◽  
Early Relapse

Abstract Overexpression of low-molecular-weight isoforms (LMWI) of cyclin E in breast cancer cells is associated with poor prognosis and could serve a novel role in breast cancer progression. LMWI originate from proteolytic processing of cyclin E, which is deregulated and hyperactive. In this study, levels of full-form/LMWI cyclin E were determined with the use of Western blot analysis in 69 Japanese breast cancer patients. LMWI cyclin E levels were significantly correlated with known parameters such as tumor grade and estrogen/progesterone receptor expression. In multivariate analysis, patient survival was significantly correlated with tumor grade but not with either form of cyclin E. LMWI was not as strong a predictor as tumor grade in this study, whereas some cases of early relapse with LMWI overexpression and lower tumor grade were reported. Thus, LMWI might be a good complementary factor to other predictors for early relapse of breast cancer.

Overexpression of microRNA-21 in the Serum of Breast Cancer Patients

MicroRNA ◽  
2019 ◽  
Vol 9 (1) ◽  
pp. 58-63
Author(s):  
Batool Savari ◽  
Sohrab Boozarpour ◽  
Maryam Tahmasebi-Birgani ◽  
Hossein Sabouri ◽  
Seyed Mohammad Hosseini
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Cancer Progression ◽  
Tumor Resection ◽  
Tumor Grade ◽  
Healthy Controls ◽  
Breast Cancer Patients ◽  
Serum Samples ◽  
Post Surgery ◽  
Polymerase Chain

Background: Breast cancer is the most common cancer diagnosed in women worldwide. So it seems that there's a good chance of recovery if it's detected in its early stages even before the appearances of symptoms. Recent studies have shown that miRNAs play an important role during cancer progression. These transcripts can be tracked in liquid samples to reveal if cancer exists, for earlier treatment. MicroRNA-21 (miR-21) has been shown to be a key regulator of carcinogenesis, and breast tumor is no exception. Objective: The present study was aimed to track the miR-21 expression level in serum of the breast cancer patients in comparison with that of normal counterparts. Methods: Comparative real-time polymerase chain reaction was applied to determine the levels of expression of miR-21 in the serum samples of 57 participants from which, 42 were the patients with breast cancer including pre-surgery patients (n = 30) and post-surgery patients (n = 12), and the others were the healthy controls (n = 15). Results: MiR-21 was significantly over expressed in the serum of breast cancer patients as compared with healthy controls (P = 0.002). A significant decrease was also observed following tumor resection (P < 0.0001). Moreover, it was found that miR-21 overexpression level was significantly associated with tumor grade (P = 0.004). Conclusion: These findings suggest that miR-21 has the potential to be used as a novel breast cancer biomarker for early detection and prognosis, although further experiments are needed.

scholarly journals Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression

Cell Cycle ◽  
2009 ◽  
Vol 8 (7) ◽  
pp. 1062-1068 ◽  
Author(s):  
Hannah Wingate ◽  
Agnes Puskas ◽  
Mylinh Duong ◽  
Tuyen Bui ◽  
Dana Richardson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Molecular Weight ◽  
Tumor Progression ◽  
Cyclin E ◽  
Low Molecular Weight

scholarly journals Cdk2 is Required for Breast Cancer Mediated by the Low-Molecular-Weight Isoform of Cyclin E

2011 ◽  
Vol 71 (9) ◽  
pp. 3377-3386 ◽  
Author(s):  
Said Akli ◽  
Carolyn S. Van Pelt ◽  
Tuyen Bui ◽  
Laurent Meijer ◽  
Khandan Keyomarsi
Keyword(s):  
Breast Cancer ◽  
Molecular Weight ◽  
Cyclin E ◽  
Low Molecular Weight

scholarly journals Androgen Receptor Expression in Triple-Negative Breast Cancer

2019 ◽  
pp. 90-94
Author(s):  
Samane Jam ◽  
Alireza Abdollahi ◽  
Sanaz Zand ◽  
Zahra Khazaeipour ◽  
Ramesh Omranipour ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Triple Negative Breast Cancer ◽  
Lymphovascular Invasion ◽  
Triple Negative ◽  
Tumor Grade ◽  
Receptor Expression ◽  
Breast Cancers ◽  
Breast Cancer Patients ◽  
Cross Sectional

Background: Triple-negative breast cancer (TNBC) accounts for 15 to 20% of all breast cancers. These patients do not benefit from hormone therapy and other targeted treatments of breast cancer. Recently, researchers proposed the use of androgen receptor (AR)-targeted therapies in this subset of patients. The rate of AR expression in TNBC patients varies from 0 to 53%. AR positivity is associated with a better outcome for breast cancer patients. The purpose of this study was to evaluate AR status in TNBC patients and its association with other demographic and pathologic features.Methods: This cross-sectional study was conducted in the Cancer Institute of Iran, affiliated with Tehran University of Medical Sciences, in 2015. Archived formalin-fixed, paraffin-embedded breast tumor blocks were evaluated to determine the AR status of the tumors. Demographic and pathologic characteristics of the patients were retrieved from the department of pathology database. Data were analyzed with SPSS 18.0.Results: Seventy-seven TNBC patients with the mean age of 45.3 ± 11.5 were assessed. Twenty-six patients (34%) showed AR expression, and 51 patients (56%) did not have AR expression. There was no significant correlation between AR status and age, tumor size, histopathologic type of tumor, or lymph node involvement. However, AR positivity had a statistically significant association with a lower tumor grade and lymphovascular invasion (P = 0.029 and P = 0.01, respectively).Conclusion: TNBC patients with AR expression tend to have lower tumor grades and higher rates of lymphovascular invasion.

Tumor-Specific Low Molecular Weight Forms of Cyclin E Induce Genomic Instability and Resistance to p21, p27, and Antiestrogens in Breast Cancer

2004 ◽  
Vol 64 (9) ◽  
pp. 3198-3208 ◽  
Author(s):  
Said Akli ◽  
Ping-Ju Zheng ◽  
Asha S. Multani ◽  
Hannah F. Wingate ◽  
Sen Pathak ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Molecular Weight ◽  
Genomic Instability ◽  
Cyclin E ◽  
Low Molecular Weight

scholarly journals Targeting low molecular weight cyclin E (LMW-E) in breast cancer

2011 ◽  
Vol 132 (2) ◽  
pp. 575-588 ◽  
Author(s):  
Angela Nanos-Webb ◽  
Natalie A. Jabbour ◽  
Asha S. Multani ◽  
Hannah Wingate ◽  
Nassima Oumata ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Molecular Weight ◽  
Cyclin E ◽  
Low Molecular Weight
Sign in / Sign up

Export Citation Format

Share Document